Ian Davis Net Worth

Ian Davis biography

Ian E. L. Davis serves as Independent Director of the Company. He is currently non-executive Chairman, Rolls-Royce Holdings plc. Mr. Davis retired from McKinsey & Company (management consulting) in 2010 as a Senior Partner, having served as Chairman and Worldwide Managing Director from 2003 until 2009. In his more than 30 years at McKinsey, he served as a consultant to a range of global organizations across the public, private and not-for-profit sectors. Prior to becoming Chairman and Worldwide Managing Director, he was Managing Partner of McKinsey's practice in the United Kingdom and Ireland. His experience included oversight for McKinsey clients and services in Asia, Europe, the Middle East and Africa, and expertise in the consumer products and retail industries. Mr. Davis is a Director Majid Al Futtaim Holding LLC, and a Senior Advisor at Apax Partners, a private equity firm.

What is the salary of Ian Davis?

As the Independent Director of Johnson & Johnson, the total compensation of Ian Davis at Johnson & Johnson is $304,979. There are 20 executives at Johnson & Johnson getting paid more, with Alex Gorsky having the highest compensation of $25,365,800.

How old is Ian Davis?

Ian Davis is 69, he's been the Independent Director of Johnson & Johnson since 2010. There are 2 older and 29 younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Ronald Williams, 70, who is the Independent Director.

What's Ian Davis's mailing address?

Ian's mailing address filed with the SEC is ONE JOHNSON & JOHNSON PLAZA, , NEW BRUNSWICK, NJ, 08933.

Insiders trading at Johnson & Johnson

Over the last 22 years, insiders at Johnson & Johnson have traded over $59,929,946 worth of Johnson & Johnson stock and bought 21,998 units worth $2,578,685 . The most active insiders traders include Hubert Joly, Anne M Mulcahy a Alex Gorsky. On average, Johnson & Johnson executives and independent directors trade stock every 21 days with the average trade being worth of $4,572,436. The most recent stock trade was executed by Robert J Decker on 30 August 2024, trading 5,635 units of JNJ stock currently worth $563,838.

What does Johnson & Johnson do?

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.

Johnson & Johnson executives and stock owners

Johnson & Johnson executives and other stock owners filed with the SEC include:

• Alex Gorsky,
  Chairman of the Board, Chief Executive Officer
• Paulus Stoffels,
  Vice Chairman- Executive Committee, Chief Scientific Officer
• Joaquin Duato,
  Vice Chairman - Executive Committee
• Joseph Wolk,
  Chief Financial Officer, Executive Vice President
• Jennifer Taubert,
  Executive Vice President - Worldwide Chairman, Pharmaceuticals
• Michael Ullmann,
  Executive Vice President, General Counsel
• Alex Gorsky,
  Exec. Chairman
• Peter Fasolo,
  Chief Human Resource Officer, Executive Vice President
• Dr. Paulus A. Stoffels M.D., Ph.D.,
  Chief Scientific Officer
• Joaquin Duato,
  CEO & Director
• Joseph J. Wolk CPA,
  Exec. VP & CFO
• Joseph J. Wolk C.P.A.,
  Exec. VP & CFO
• Jennifer L. Taubert,
  Exec. VP & Worldwide Chairman of Pharmaceuticals
• Anne Mulcahy,
  Lead Independent Director
• Charles Prince,
  Independent Director
• Mary Beckerle,
  Independent Director
• Ronald Williams,
  Independent Director
• D. Scott Davis,
  Independent Director
• A. Eugene Washington,
  Independent Director
• Jennifer Doudna,
  Independent Director
• Mark McClellan,
  Independent Director
• Ian Davis,
  Independent Director
• Marillyn Hewson,
  Independent Director
• Mark Weinberger,
  Independent Director
• Hubert Joly,
  Independent Director
• Christopher DelOrefice,
  Vice President, Investor Relations
• Kathryn Wengel,
  Executive Vice President, Chief Global Supply Chain Officer
• Michael Sneed,
  Executive Vice President - Global Corporate Affairs and Chief Communication Officer
• Thibaut Mongon,
  Executive Vice President, Worldwide Chairman, Consumer
• Ashley McEvoy,
  Executive Vice President - Worldwide Chairman, Medical Devices
• Dr. Guy J. Lebeau M.D.,
  Group Chairman of MD&D Bus. - EMEA
• Dr. Peter M. Fasolo Ph.D.,
  Exec. VP & Chief HR Officer
• Michael H. Ullmann,
  Exec. VP & Gen. Counsel
• Jessica Moore,
  VP of Investor Relations
• Ashley Watson,
  Chief Compliance Officer
• James Swanson,
  Exec. VP & Global CIO
• Robert J. Decker Jr.,
  Controller & Chief Accounting Officer
• James Cullen,
  Director
• Stephen J Cosgrove,
  
• Leo F Mullin,
  Director
• Michael M E Johns,
  Director
• Robert J Decker,
  VP Corporate Controller
• Elizabeth Forminard,
  Executive VP, General Counsel
• Ronald A Kapusta,
  Controller, CAO
• Susan L Lindquist,
  Director
• Gary J Pruden,
  Exec VP, WW Chair, Med Devices
• William D Perez,
  Director
• Jorge S. Mesquita,
  Exec VP, WW Chair, Consumer
• Dominic J Caruso,
  Chief Financial Officer
• Timothy Schmid,
  EVP, WW Chair, MedTech
• Mary Sue Coleman,
  Director
• David Satcher,
  Director
• William C Weldon,
  Chairman/CEO
• Arnold G Langbo,
  Director
• Russell C Deyo,
  Vice President, Administration
• Kaye I Foster Cheek,
  VP, Human Resources
• Colleen A Goggins,
  Member, Executive Committee
• Sherilyn S Mc Coy,
  Member, Executive Committee
• Donald M Jr. Casey,
  Member, Executive Committee
• Nicholas J Valeriani,
  Vice President,Human Resources
• Christine A Poon,
  Executive Committee Member
• Joseph C Scodari,
  Executive Committee Member
• Steven Reinemund,
  Director
• Ann Dibble Jordan,
  Director
• Robert J Darretta,
  Member, Executive Committee
• Per A Peterson,
  Executive Committee Member
• Michael J Dormer,
  Member, Executive Committee
• Joann Heffernan Heisen,
  Member, Executive Committee
• Gerard N Burrow,
  Director
• Henry B Schacht,
  Director
• M Judah Folkman,
  Director
• Roger S Fine,
  Vice President General Counsel
• James T Lenehan,
  Vice Chairman
• Brian D Perkins,
  Executive Committee Member
• Robert N Wilson,
  
• Nadja West,
  Director
• Vanessa Broadhurst,
  EVP, Global Corp Affairs
• Mathai Mammen,
  EVP, Pharm, R&D
• William Hait,
  EVP, Chief EI and Med Officer
• Darius Adamczyk,
  Director
• James D. Swanson,
  EVP, CIO
• John C Reed,
  EVP, Innovative Medicine, R&D
• Paula A Johnson,
  Director
• Eugene A. Woods,
  Director